National vaccine regulatory agencies and pharmaceutical companies will now use this guidance to develop, produce and license influenza vaccines for the following season.
WHO organises consultations with an advisory group of experts twice a year to analyse influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS). The organisation then issues recommendations on the composition of the influenza vaccines for the following influenza season.
